Global Information
회사소개 | 문의 | 비교리스트

부신피질암 : 파이프라인 리뷰

Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline Review, H1 2020

리서치사 Global Markets Direct
발행일 2020년 04월 상품 코드 213047
페이지 정보 영문 162 Pages
가격
US $ 2,000 ₩ 2,396,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,792,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,189,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


부신피질암 : 파이프라인 리뷰 Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline Review, H1 2020
발행일 : 2020년 04월 페이지 정보 : 영문 162 Pages

부신피질암은 부신피질에 종양이 증식해 생기는 희귀질환입니다. 발병인자는 성별, 부신에 영향을 미치는 유전질환, 노화, 흡연 등이며 증상에는 고혈당, 고혈압, 하지 근력 저하, 흉부 및 복부 지방의 과잉 축적, 수염 및 체모 증가, 목소리의 남성화 등이 있습니다.

세계 각국의 부신피질암(Adrenocortical Carcinoma) 치료용 파이프라인 제품 개발 상황에 대해 분석했으며, 파이프라인 제품의 최신 동향, 임상시험 각 단계 제품 목록, 주요 기업 개요, 주요 치료제 개요(제품 개요, 작용기전, 연구개발(R&D) 진전 상황), 최신 업계 동향 등의 조사 결과를 전해드립니다.

목차

서론

  • 분석 범위

부신피질암 개요

치료제 개발

  • 부신피질암용 파이프라인 제품 : 개요
  • 기업별 치료제
  • 기업에서 개발중인 제품

부신피질암 : 치료제 평가

  • 표적별
  • 작용기전별
  • 투여 경로별
  • 분자 종류별

부신피질암 치료제 개발 참여 기업

  • ArQule Inc
  • EnGeneIC Ltd
  • Exelixis Inc
  • Merck KGaA
  • Millendo Therapeutics Inc
  • Orphagen Pharmaceuticals Inc

부신피질암 : 치료제 프로파일

부신피질암 치료제 : 개발 휴지 상태인 프로젝트

부신피질암 치료제 : 개발이 중지된 제품

부신피질암 관련 제품 개발 마일스톤

  • 주목해야 할 최신 동향과 프레스 릴리스

부록

도표

LSH 17.06.05

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

List of Tables

  • Number of Products under Development for Adrenocortical Carcinoma (Adrenal Cortex Cancer), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Bristol-Myers Squibb Co, H1 2020
  • Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Exelixis Inc, H1 2020
  • Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Infinity Pharmaceuticals Inc, H1 2020
  • Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Merck & Co Inc, H1 2020
  • Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Merck KGaA, H1 2020
  • Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Millendo Therapeutics Inc, H1 2020
  • Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Orphagen Pharmaceuticals Inc, H1 2020
  • Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Seneca Therapeutics Inc, H1 2020
  • Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Trovagene Inc, H1 2020
  • Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Y-mAbs Therapeutics Inc, H1 2020
  • Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Dormant Projects, H1 2020
  • Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Discontinued Products, H1 2020

List of Figures

  • Number of Products under Development for Adrenocortical Carcinoma (Adrenal Cortex Cancer), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Top 10 Molecule Types, H1 2020

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Adrenocortical Carcinoma - Pipeline Review, H1 2020, provides an overview of the Adrenocortical Carcinoma (Oncology) pipeline landscape.

Adrenal cortex cancer (ACC) is a rare disease. It is caused by a cancerous growth in the adrenal cortex, which is the outer layer of the adrenal glands. Predisposing factors include female, hereditary disease that affects the adrenal glands, age and smoking. Symptoms include high blood sugar and pressure, muscle weakness in the legs, excessive weight gain in chest and abdomen, early signs of puberty in children, increased facial and body hair, particularly in females and deepened voice in females.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Adrenocortical Carcinoma - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Adrenocortical Carcinoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Adrenocortical Carcinoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Adrenocortical Carcinoma (Adrenal Cortex Cancer) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Discovery stages are 4, 5 and 1 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.

Adrenocortical Carcinoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Adrenocortical Carcinoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Adrenocortical Carcinoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Adrenocortical Carcinoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Adrenocortical Carcinoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Adrenocortical Carcinoma (Oncology)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Adrenocortical Carcinoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Adrenocortical Carcinoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Overview
  • Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Therapeutics Development
  • Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Therapeutics Assessment
  • Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Companies Involved in Therapeutics Development
  • Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Drug Profiles
  • Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Dormant Projects
  • Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Discontinued Products
  • Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Product Development Milestones
  • Appendix
Back to Top
전화 문의
F A Q